These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
564 related articles for article (PubMed ID: 32033764)
1. How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. Henry ZH; Argo CK Gastroenterol Clin North Am; 2020 Mar; 49(1):45-62. PubMed ID: 32033764 [TBL] [Abstract][Full Text] [Related]
2. Liver fibrosis markers of nonalcoholic steatohepatitis. Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988 [TBL] [Abstract][Full Text] [Related]
3. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111 [TBL] [Abstract][Full Text] [Related]
5. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. Zhou JH; Cai JJ; She ZG; Li HL World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425 [TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908 [TBL] [Abstract][Full Text] [Related]
8. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Tsai E; Lee TP Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062 [TBL] [Abstract][Full Text] [Related]
11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
19. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice. Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. Theel W; Boxma-de Klerk BM; Dirksmeier-Harinck F; van Rossum EFC; Kanhai DA; Apers J; van Dalen BM; de Knegt RJ; Holleboom AG; Tushuizen ME; Grobbee DE; Wiebolt J; Castro Cabezas M Obes Rev; 2022 Aug; 23(8):e13481. PubMed ID: 35692179 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]